• Gilberto Barranco-Lampón, Raúl Martínez-Castro, Luara Arana-Luna, José Luis Álvarez-Vera, Flavio Rojas-Castillejos, Rosalinda Peñaloza-Ramírez, Adrián Alejandro Carballo-Zarate, Irma Olarte-Carrillo, Jaime Israel-García Minamy, Javier López-Salazar, Juan José Navarrete, Arturo Espinosa-Partida, Yanet Ventura-Enríquez, Josué Isel Ruiz-Contreras, Oyuky Gissell Aguirre-Reyes, Irene Anaya-Cuéllar, Jocelyn Aguilar-Luévano, Hugo Francisco Díaz-Ramírez, Wilfrido Herrera-Olivares, José Antonio Aguilar-Hidalgo, Luisa Ma Alcívar-Cedeño, Álvaro Hernández-Caballero, Lourdes Elena Galaz-Cordero, Peña-CelayaJosé Antonio de laJAServicio de Hematología, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México., Pamela Elena Báez-Islas, Ramón Alberto Bates-Martín, Ana Ma de la Luz Cano-León, Ma Eugenia Espitia-Ríos, Diego Barbosa, Javier Morales-Adrián, Martín Jacobo Pacheco, Nancy Delgado-López, Yvette Neme-Yunes, Alba Edna Moralws-Hernández, Aldo Mújica-Martínez, Alejandra Betsabé Pérez-Lizardi, Karen Daniela Pérez-Gómez, Gabriel Barragán-Ibáñez, Adolfo Martínez, Karen Flores-Ordúñez, Paulina Ramírez-Hoyos, Rosales-LópezMa de Los ÁngelesMLÁServicio de Hematología, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México., Brenda Lizeth Acosta-Maldonado, Marco Alejandro Jiménez-Ochoa, Katheryn Betsabé Garzón-Velásquez, Eleazar Hernández-Ruiz, Bosco Martín McNally-Guillén, Erick Eduardo Saucedo-Montes, Carolina Aguilar-Andrade, Cindy Lissette Vivas-Arteaga, Lidia Virginia Guerra-Alarcón, Andrea Iracema Milán-Salvatierra, Dafne Itzel Campa-Monroy, Xóchitl Cota-Rangel, Patricia Estrada-Domínguez, Alinka Socorro García-Camacho, Carolina García-Castillo, Luisa Iztacihuatl Banda-García, Vania Rodríguez-Sánchez, Luis Antonio Meillón-García, Elizabeth Urbina-Escalante, Mario Alberto Martínez-Ramírez, Sergio José Loera-Fragoso, Jorge Martínez-Coronel, Nidia Zapata-Canto, Sue Cynthia Gómez-Cortés, Jesús Emanuel Medina-Coral, Liliana Mójica-Balderas, Juan Manuel Pérez-Zúñiga, Fernando Jacobo Pérez, Luis López-ArroyoJoséJServicio de Hematología, Hospital Central Militar, SEDENA, Ciudad de México, México., Juan Francisco Zazueta-Pozos, Eduardo Romero-Martínez, Hilda Romero-Rodelo, Ana Laura Tapia-Enríquez, Emely Johanny Soriano-Mercedes, Óscar Salazar-Ramírez, Shendel Paulina Vilchis-González, Fredy Tepepa-Flores, and Martha Alvarado-Ibarra.
• Servicio de Hematología, Hospital General de México, Ciudad de México, México.
• Gac Med Mex. 2022 Jan 1; 158 (Supl 1): 384438-44.

AbstractThe objective of this work is to generate recommendations on the management of allogeneic stem cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic review of articles published between 1999 and 2015 (January) was used as a source of scientific evidence. The recommendations were produced through a Delphi process involving a panel of 23 experts appointed by the European LeukemiaNet and the European Blood and Marrow Transplantation Group. Key questions included patient selection, donor selection, pre-transplant management, conditioning regimen, post-transplant management, prevention, and management of post-transplant relapse. Patients with intermediate-2 or high-risk disease and age < 70 years should be considered candidates for allo-SCT. Patients with intermediate-risk 1 disease and age < 65 years should be considered candidates if they have refractory transfusion-dependent anemia, or a peripheral blood (PB) blast percentage > 2%, or adverse cytogenetics. Splenectomy before transplantation must be decided on a case-by-case basis. Patients with intermediate-2 or high-risk disease who lack a human leukocyte antigen (HLA)-matched sibling or unrelated donor should be enrolled in a protocol that uses HLA non-identical donors. PB was considered the most appropriate source of hematopoietic stem cells for transplants from HLA-matched unrelated donors and siblings. The optimal intensity of the conditioning regimen has yet to be defined. Strategies such as discontinuation of immunosuppressive drugs, infusion of donor lymphocytes, or both were considered adequate to prevent clinical relapse. In conclusion, we provide consensus-based recommendations aimed at optimizing allo-SCT in PMF. Unmet clinical needs were highlighted.Copyright: © 2022 Permanyer.

8 keywords...

hide…